In this prospective review of 15,104 women with breast cancer with 11-year median follow-up, CBC was seen in 5.3%, with a significant increase in women with BRCA1, BRCA2, and CHEK2 mutations (p < 0.05). Here, CHEK2 is linked to breast cancer.